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Background: HIV genome is packaged and organized in a conical capsid, which is made up of ~1,500 copies of
the viral capsid protein p24 (CA). Being a primary structural component and due to its critical roles in both late and
early stages of the HIV replication cycle, CA has attracted increased interest as a drug discovery target in recent
years. Drug discovery studies require large amounts of highly pure and biologically active protein. It is therefore
desirable to establish a simple and reproducible process for efficient production of HIV-1 CA.
Result: In this work, 6-His-tagged wild type CA from HIV-1 (NL4.3) was expressed in rare tRNA-supplemented
NiCo21(DE3) Escherichia coli, and its production was studied in shake flask culture condition of expression. Influences
of various key cultivation parameters were examined to identify optimal conditions for HIV-1 CA production. It was
found that a culture temperature of 22°C and induction with 0.05 mM IPTG at the early stage of growth were ideal,
leading to a maximum biomass yield when grown in Super broth supplemented with 1% glucose. With optimized
culture conditions, a final biomass concentration of ~27.7 g L-1 (based on optical density) was obtained in 12 hours
post-induction, leading to a yield of about ~170 mg L-1 HIV-1 CA. A two-step purification strategy (chitin beads +
IMAC) was employed, which efficiently removed metal affinity resin-binding bacterial proteins that contaminate
recombinant His-tagged protein preparation, and resulted in highly pure HIV-1 CA. The purified protein was capable
of polymerization when tested in an in vitro polymerization assay.
Conclusions: By using this optimized expression and purification procedure, milligram amounts of highly pure
and polymerization-competent recombinant HIV-1 CA can be produced at the lab-scale and thus used for further
biochemical studies.Background
Human immunodeficiency virus (HIV) causes acquired
immunodeficiency syndrome (AIDS), a progressive im-
mune disorder that allows life-threatening opportunistic
infections, cardiovascular diseases, and cancers to thrive.
The capsid protein p24 (CA) plays seminal roles in both
late and early stages of the HIV replication cycle [1].
HIV-1 CA is considered an important target for develop-
ing novel drugs to treat AIDS. For example, a small mole-
cule, CAP-1, and two versions of a peptide inhibitor, CAI
and NYAD-1, have been reported that target HIV-1 CA* Correspondence: ali2@amdi.usm.edu.my
†Equal contributors
1Oncological and Radiological Sciences, Advanced Medical and Dental
Institute, Universiti Sains Malaysia, Bertam, 13200 Kepala Batas, Pulau Pinang,
Malaysia
Full list of author information is available at the end of the article
© 2013 Teow et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orin vitro and interfere with its function in infected cells
[2-4]. In another study, two small compounds PF-3450074
and PF-3759857 have shown to be active against HIV-1 in
low μM concentration and latter (PF-3759857) against
HIV-2 too [5]. More recently, compounds derived from
benzodiazepines (BD) and the benzimidazoles (BM) series
of chemicals have shown to prevent virion release and
inhibited the formation of the mature capsid [6]. These
studies require milligram quantities of the CA in soluble
and active form. However, high commercial cost may limit
its use in studies carried out at academic level.
The HIV-1 CA has been produced in bacterium
Escherichia coli [7-11], yeast Pichea pastoris [12], plants
[13-15], and baculovirus-insect cells [16]. However,
existing methodologies rely on sequence modifications
and several purification rounds involving precipitationtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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host’ contaminating proteins.
Due to the presence of rare codons and low solubility
of over-expressed recombinant protein, it has been chal-
lenging to obtain large quantities of HIV-1 CA. The aim
of this study was to establish a convenient and relatively
fast purification procedure for obtaining large amounts
of biologically active HIV-1 CA at the laboratory scale.
The expression and purification method described here
is simple, expresses protein from the wild type p24 gene,
and yields up to 170 mg of highly pure HIV-1 CA suit-
able for polymerization experiments.
Methods
Bacterial strains, plasmids, and media
The E. coli strains DH5α (NEB #C2987H) and NiCo21
(DE3) (NEB #C2529H) were used for cloning and ex-
pression experiments respectively. Bacteria were aerobic-
ally grown in LB broth (10 g L-1 bacto-tryptone; 5 g L-1
yeast extract; 5 g L-1 NaCl; pH 7.0) or on LB agar (10 g L-1
bacto-tryptone; 5 g L-1 yeast extract; 5 g L-1 NaCl;
15 g L-1 Agar; pH 7.0) at various temperatures and in the
absence or presence of Ampicillin (100 μg mL-1) and/or
Chloramphenicol (25 μg mL-1). Bacterial strains were
stored in LB broth plus 50% glycerol at −80°C. In some ex-
periments, NiCo21(DE3) were transformed with rare
tRNA supplementing plasmids pACYC-RIL (Stratagene),
pRARE2 (Novagen), and pLysSRARE2 (Novagen). In some
experiments, NiCo21(DE3) were grown in M9 broth
(0.5 g L-1 NaCl; 1 g L-1 NH4Cl; 3 g L
-1 KH2PO4; 6.78 g L
-1
Na2HPO4.; 2 mMMgSO4; 0.1 mM CaCl2; 10 g L
-1 glucose.
pH 7.0), Super broth (32 g L-1 bacto-tryptone; 20 g L-1 yeast
extract; 5 g L-1 NaCl; pH 7.0), or Terrific broth (12 g L-1
bacto-tryptone; 24 g L-1 yeast extract; 8 mL L-1 glycerol;
2.2 g L-1 KH2PO4; 9.4 g L
-1 K2HPO4. pH 7.0).
Construction of plasmid expressing HIV-1 CA (pSA-HP24-6His)
Construction scheme of pSA-Hp24-6His is given in
Figure 1A.
Preparation of insert (p24 with 5′ NdeI and 3′ SacI restriction
enzyme sites)
The pNL4.3 plasmid (GenBank accession no. M19921)
harboring complete genome of HIV-1 NL4.3 was ob-
tained through the NIH AIDS Reagent Program and
used as the template for PCR amplification of p24 gene
encoding 231 residues of wild-type capsid protein p24.
The p24 gene was PCR amplified using forward primer
P24-F-NdeI (5′ GGTGGTCATATGCCTATAGTGCAG
AACCTCCAG 3′, NdeI restriction site is in italics) and
reverse primer P24-R-SacI (5′ GGTGGTGAGCTC
CAAAACTCTTGCTTTATGGCC 3′, SacI restriction
site is in italics) with high fidelity Pfu DNA polymerase
(Thermo Scientific #EP0572) following manufacturer’ssupplied protocol. The PCR product (714 bp amplicon)
was purified using NucleoSpin® Gel and PCR Clean-up
kit (MACHEREY-NAGEL GmbH & Co #740609) and
restricted with NdeI (NEB # R0111L) and SacI (NEB
#R0156L) restriction enzymes following manufacturer’s
supplied protocol.
Preparation of vector
Expression vector pMXB10 (NEB) was amplified by PCR
using primers pMXB10-F-SacI-6His (5′ CTCGAGCTC
CACCATCACCATCACCATTGACTGCAGGAAGGGG
ATC 5′, SacI restriction site is in italics) and pMXB10-
R-NdeI (5′ GGCTCTTCCCATATGTATATCTCC 3′,
NdeI restriction site is in italics) with Pfu polymerase.
The PCRed plasmid (5.914 kb) was gel purified using
NucleoSpin® Gel and PCR Clean-up kit and restricted
with NdeI and SacI restriction enzymes.
Insert and vector were ligated in a 1:3 molar ratio
using T4 DNA ligase (NEB #M0202S), transformed in
chemically competent DH5α E. coli cells, and selected
on LB-agar plates (containing 100 ug mL-1 Ampicillin)
after 18 h incubation at 30°C. A total of 10 randomly se-
lected bacterial colonies were subjected to colony PCR
using a vector-specific primer T7Up-F (5′ GATCCCGC
GAAATTAATACG 3′) and an insert-specific primer
P24-R (5′ GTGGAGCTCCAAAACTCTTGC 3′). Amp-
lification of a 806 bp PCR product will be confirmatory
for the successful cloning of P24 insert in pSA vector.
Plasmid DNA was isolated from 3 colony PCR-positive
clones and subjected to restriction analysis and DNA se-
quencing. We named this recombinant plasmid pSA-
Hp24-6His.
Expression of capsid protein p24 in pSA-HP24-6His-
transformed NiCo21(DE3) E. coli
Sequencing-confirmed pSA-Hp24-6His was transformed
into chemically competent NiCo21(DE3) E coli and
transformants were selected on LB-Agar containing
100 μg mL-1 Ampicillin. For expression, a single colony
from a freshly streaked (~18h) plate was inoculated in
10 mL of Ampicillin-supplemented LB broth. The starter
culture was grown at 30°C while shaking at 250 rpm
until the OD600 was approximately 1. The bacterial cells
were centrifuged at 3000 × g for 10 min, re-suspend in
fresh LB broth, and used to inoculate the main culture
at 1:20 dilution (0.5 OD600). The culture was grown at
30°C while shaking at 250 rpm until the OD600 reached
to 0.5-0.6. The cultures were then equilibrated to induc-
tion temperature (30, 22, or 18°C) and induced with vari-
ous concentrations of Isopropylthio-β-galactoside (IPTG).
Induced cultures were grown for different time lengths (6
hours at 30°C; 12 hours at 22°C; 16 hours at 18°C) and
bacterial cells were pelleted by centrifugation at 5000 × g
for 10 minutes in pre-weighed centrifuge tubes/bottles.
Figure 1 Construction and verification of pSA-Hp24-6His vector. We PCR amplified the p24 gene from pNL4.3 and cloned at NdeI/SacI
restriction sites in inversely PCRed pMXB10 vector (A). Agarose gel electrophoresis analysis (B). Lane 1, 100 bp DNA ladder (NEB#N0467S); Lane 2,
PCR amplified 714 bp p24; Lane 3, inversely PCRed 5.91 kb pSA vector; Lane 4, representative colony PCR (806 bp); Lane 5, restriction analysis of
pSA-Hp24-6His with NdeI/SacI (5.89 kb vector backbone + 702 bp insert) ; Lane 6, 1 kb DNA ladder (NEB #N0468S).
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pACYC-RIL, pRARE2, and pLysSRARE2
The NiCo21(DE3) were individually transformed with
pACYC-RIL, pRARE2, and pLysSRARE2 vectors and the
transformants were selected on LB agar plates contain-
ing 25 μg mL-1 Chloramphenicol. Transformants were
grown out and competent cells were prepared following
Inoue’s protocol [17]. The pACYC-RIL, pRARE2, and
pLysSRARE2-containing NiCo21(DE3) were then trans-
formed with pSA-Hp24-6His vector and the transfor-
mants were selected on LB agar plates containing
Ampicillin (100 μg mL-1) and Chloramphenicol (25 μg
mL-1). Cultures were grown in presence of both the anti-
biotics and the expression protocol given above was es-
sentially followed. To study the effect of various culture
media on the expression of HIV-1 CA, cultures weregrown in 1% glucose-supplemented M9 minimal broth,
LB Broth, Terrific Broth, and Super Broth essentially fol-
lowing the expression protocol given above.
Cell lysis and protein extraction
To every 1 gram of bacterial cell pellet, 4 mL of B-PER
extraction reagent (Thermo Scientific #78248) supple-
mented with DNAse I (Thermo Scientific #90083) and
protease cocktail (Thermo Scientific #87785) was added.
The mixture was incubated at 22°C for 30 min on a
nutator shaker. Soluble and insoluble proteins were par-
titioned by centrifuging bacterial cell lysate at 15,000 × g
for 5–10 minutes at 4°C. Clear supernatant containing
soluble proteins was passed through 0.45 μ membrane
(Millipore #HPWP04700) and used for immobilized-
metal affinity chromatography (IMAC). Insoluble lysed
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with phosphate buffered saline (PBS). Both, soluble
and insoluble fractions were stored in small aliquots
at −80°C for further analysis.
Protein assays, SDS-PAGE, and immunoblotting
Total protein was quantitated using Qubit® Protein
Assay Kit (Life Technologies – Invitrogen # Q33211) in
a Qubit fluorometer (Life Technologies – Invitrogen).
For SDS-PAGE, protein fractions were mixed with 5X
reducing sample buffer (Thermo Scientific #39000), re-
solved on 12% (w/v) polyacrylamide gels, and detected
with Coomassie blue G250 as described previously [18].
For immunoblot analysis, proteins were electroblotted
onto the Hybond ECL nitrocellulose membrane (GE
Healthcare Life Sceinces #RPN2020D). The membrane
was washed in Tris-buffered saline (TBS) for 5 min,
blocked with 5% nonfat milk in TTBS (TBS with 0.1%
Tween 20) for 1 h by shaking at room temperature,
processed for immunoblotting using either primary anti-
His MAb (Thermo Scientific #MA1-21315) or anti-p24
MAb (NIH AIDS reagent program # 71–31) with shak-
ing at 4°C overnight followed by a secondary HRP-
conjugated IgG (H + L) antibody (Thermo Scientific #
32430). Protein bands were detected by SuperSignal
West Pico Chemiluminescent substrate (Thermo Scien-
tific # 34080) followed by image capture using
FluorChem M Imager (ProteinSimple). Band intensities
were determined using software AlphaView SA version
3.4.0. (ProteinSimple).
Purification of HIV-1 CA
Recombinant HIV-1 CA was purified in two steps. First,
the soluble protein fraction was pre-adsorbed on chitin
resin (NEB #S6651) to get rid of bacterial Histidine-rich
proteins. An appropriate amount of Chitin beads was
added into a plastic chromatography column (BioRad
#732-1010) and equilibrated in two resin-bed volumes of
Equilibration/Wash Buffer (50 mM sodium phosphate,
500 mM sodium chloride, 10 mM imidazole; pH 7.4).
Soluble protein fraction was diluted with an equal volume
of Equilibration/Wash Buffer and added to the equili-
brated chitin beads (1 ml of chitin resin for each volume
of lysate corresponding to 1 gram of NiCo21(DE3) cell
pellet). The column was then placed on an end-over-end
rotator and revolved for 30 minutes at 4°C. Void volume
containing target protein was eluted by gravity flow and
used for IMAC.
For IMAC, HisPur™ Cobalt resin (Thermo Scientific
#89965) was used following manufacturer’s protocol.
Briefly, an appropriate amount of cobalt resin was added
in 15 mL centrifuge tube and washed with two resin-bed
volumes of Equilibration/Wash Buffer. The chitin bead
pre-adsorbed soluble protein fraction was combinedwith equilibrated cobalt resin and mixed on an end-
over-end rotator for 60 minutes at 4°C. The resin was
then washed with Equilibration/Wash Buffer until the
absorbance at 280 nm reached to the baseline. Bound
protein was eluted using one resin-bed volume of Elu-
tion Buffer (50 mM sodium phosphate, 500 mM sodium
chloride, 150 mM imidazole; pH 7.4). This step was re-
peated 2–3 times while saving individual fractions. Frac-
tions were analyzed by SDS-PAGE/Western blot,
dialyzed against phosphate buffered saline (PBS) using
Slide-A-Lyzer Dialysis Cassettes, 7K MWCO (Thermo
Scientific #66710) and stored at −80°C in small aliquots.
Purification of HIV-1 CA on FPLC
The HIV-1 CA was purified using TALON® Superflow™
cobalt-based IMAC column on an FPLC system (AKTA
purifier 900, GE). All buffers were prepared in deionized
water; filtered through 0.2μm membrane, and degassed
for 15 min. Column and all buffers were equilibrated to
room temperature before use. The column was con-
nected to the chromatography system by ‘drop-to-drop’
method to avoid introducing air into the system. The
column was equilibrated with 5 column volumes (CVs)
of Binding buffer (50 mM sodium phosphate, 300 mM
NaCl, pH 7.4). Sample was diluted 1:1 with Binding buf-
fer and transferred into large-volume sample loop
(Superloop 50 mL, GE) for sample loading. After sample
loading, the column was washed with 10 CVs of Wash
buffer (50 mM sodium phosphate, 300 mM NaCl, 5 mM
imidazole, pH 7.4) until the absorbance reached a steady
baseline. Protein was eluted in a linear imidazole gradi-
ent (5-150 mM in 50 mM sodium phosphate, 300 mM
NaCl, pH 7.4) and collected in 1 mL fractions. The puri-
fied fractions were then analyzed by SDS-PAGE, dialyzed
against phosphate buffered saline (PBS) using Slide-A-
Lyzer Dialysis Cassettes, 7K MWCO (Thermo Scientific
#66710), and stored at −80°C in small aliquots. The col-
umn was washed with 5 CVs of 20% ethanol and stored
at 4°C.
Polymerization assay for HIV-1 CA
A turbidometric assay was used to study in vitro
polymerization of HIV-1 CA as described previously
[19]. Final concentration of purified CA (40-80 μM) was
mixed with 50 mM sodium phosphate buffer (pH8.0) in
a total volume of 250 μL. The CA assembly was induced
by adding 250 μL of 2.0 M NaCl (final concentration) in
50 mM sodium phosphate buffer, pH8.0. The mixture
(500 μL) was briefly vortexed, immediately transferred to
a silica cuvette (10 mm path length), and spectrophotomet-
rically read at 350 nm wavelength at room temperature.
The absorbance measurements were made every 10s for
up to 60 min. The assembly rate was then set by plotting
the absorbance versus time.
Teow et al. BMC Biotechnology 2013, 13:107 Page 5 of 14
http://www.biomedcentral.com/1472-6750/13/107For polymerization inhibition, 50 μM purified CA was
mixed with various concentrations (1, 5, 10 μM) of CA-
specific anti-p24 antibody (NIH AIDS reagent program
# 71–31) in 50 mM sodium phosphate buffer (pH8.0) in
a total volume of 250 μL. The reaction was incubated at
room temperature for 30 minutes. The CA assembly
was induced by adding 250 μL of 2.0 M NaCl and
polymerization monitored as described above. Anti-
Acetylcholinesterase (AChE) antibody, clone AE-1
(Merck Millipore # MAB303) was used as negative con-
trol at a final concentration of 20 μM.
Immunization and HIV-1 CA-specific antibody detection
Two 6-weeks old female BALB/c mice were individually
primed by a single intradermal injection of 100 μg/100 μL
CA in complete Freund’s Adjuvant (CFA). Mice were
boosted with three successive injections of 100 μg/100 μL
CA in Incomplete Freund’s Adjuvant (IFA) at an interval
of two weeks. Serum was prepared from blood samples
and serially diluted from 1:1000 to 1:100,000 and sub-
jected to ELISA and used for immunoblot analysis.
293T cell culture and transfection
The 293T cells (ATCC #CRL-11268) were maintained in
DMEM (Sigma #D5030) supplemented with 10%FBS
(Life technologies # 16000–044) at 37°C in presence of
5% CO2. Cells (1×10
5) were transfected with 0.5 μg of
pNL4.3 (prepared using Endotoxin-free plasmid,
Macherey Nagel # 740420) using 2 μL of X-tremeGene
HP transfection reagent (Roche #06366236001) follow-
ing supplied protocol. Cells were harvested 48 hours
post-transfection, lysed with M-Per lysis reagent
(Thermo Scientific #78503), and subjected to SDS-
PAGE/Western blot analysis.
Results
Construction of plasmid expressing HIV-1 CA
To express HIV-1 capsid protein p24, we chose prokary-
otic expression vector pMXB10 due to its ability of high
level heterologous protein expression in BL21(DE3) E.
coli. The ‘ATG’ initiation codon is the part of NdeI re-
striction site and located at an optimal distance of 8 nu-
cleotides from the ribosome binding site (RBS). We did
not aim to express capsid protein p24 as a fusion protein
with intein-CBD (for which the pMXB10 vector was ori-
ginally designed) and therefore, we took out the entire
1.938 kb MBP-Mxe GyrA intein-CBD fragment by PCR
amplification of the pMXB10. We also introduced a SacI
restriction site followed by 21 nucleotides encoding a
6His tag and a stop codon as shown in Figure 1A. Clon-
ing of a 714 bp amplicon encoding 231 residues of wild-
type HIV-1 capsid protein p24 at NdeI/SacI sites
resulted in a 6.595 kb recombinant plasmid pSA-Hp24-
6His. We verified the pSA-Hp24-6His construct byrestriction enzyme analysis (Figure 1B) and DNA se-
quencing (data not shown). The mRNA sequence encod-
ing the capsid protein p24 is transcribed from an
inducible T7 promoter and the resulting protein has a
6His tag at its carboxy-terminal to facilitate IMAC-
mediated purification.
Expression of HIV-1 CA in NiCo21(DE3) E. coli
We used NiCo21 (DE3) to express 6His-tagged HIV-1
CA using shake flask culture condition of expression.
Plasmids containing retroviral sequences are instable in
E. coli [20], especially when grown at 37°C. Therefore,
we cultured the pSA-Hp24-6His-trandformed NiCo21
(DE3) at 30°C until the OD600 reached to 0.5-0.6. We
then induced the cultures with 0.4 mM IPTG and con-
tinued incubation at 30°C for another 6 hours while
shaking. When subjected to SDS-PAGE analysis, the
overexpressed CA appeared as approximately 24 kDa
band in the IPTG-induced fractions (Figure 2, left
panel). Overexpressed CA was present in both, insoluble
(Figure 2, lane IS) and soluble fraction (Figure 2, lane S).
Immunoblot analysis with anti-CA antibody confirmed
that the overexpressed protein was HIV-1 CA (Figure 2,
right panel). On the western blot, just above the CA
band, a 25-26 kDA band was observed. Either it is a host
protein that binds to CA or it is a product of transcrip-
tional read-through. Since the anti-p24 antibody does
not bind to the host proteins, we anticipate that this
anti-p24 reactive 25-26 kDA band is a product of tran-
scriptional read-through.
Optimization of IPTG concentration and induction
temperature
Since induction with lower IPTG concentrations and/or
at lower temperature may result in improved solubility
of overexpressed protein [21], we tested various IPTG
concentrations (0–0.4 mM) and induction temperatures
(30, 22, and 18°C). Expression of HIV-1 CA was optimal
at 0.05 mM of IPTG as determined by western blot ana-
lysis (Figure 3A). More overexpressed protein was
present in soluble fraction compared to in-soluble frac-
tion when cultures were induced with 0.05 mM IPTG
and grown at 18°C for 16 hours (Figure 3B, lanes 8&9).
However, larger amounts of CA were present in cultures
induced with 0.05 mM IPTG and grown at 22°C for 12
hours (Figure 3B, lanes 5&6).
Effect of rare tRNA supplementation on HIV-1 CA
production in NiCo21(DE3) E. coli
Over-expression of recombinant proteins in E. coli may
be significantly reduced or even stalled if the ORF that
codes for the protein uses “rare” codons that are infre-
quently used by E. coli [21,22]. When subjected to ‘rare’
codon analysis, 576 bp ORF coding for HIV-1 CA found
Figure 2 SDS-PAGE/immunoblot analysis of recombinant HIV-1 CA. NiCo21(DE3) E. coli were transformed with pSA-Hp24-6His vector and
grown at 30°C for 6 hours, either induced with 0.4 mM IPTG, or un-induced. Cells were processed as described in Methods and labeled as whole
cell lysate (WCL), insoluble fraction (IS), and soluble fraction (S). Eight microliter of each sample (WCL, IS, S) was mixed with 4X loading dye and
electrophoresed on 12% gel. Proteins were transferred to nitrocellulose membrane and stained with MemCode™ Reversible Protein Stain Kit
(Pierce) and photographed (left panel). Membrane was then destained and subjected to immunoblot analysis using primary anti-p24 antibody
and secondary anti-Mouse antibody. Membrane was developed using enhanced chemilumenscent reagent (Pierce) and image was captured
(right panel). Lane M1, BenchMark Pre-stained protein ladder; Lanes WCL, whole cell lysate; Lanes IS, insoluble fraction; Lanes S, soluble fraction;
Lane M2, MagicMark XP Western Protein Standard.
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arginine at positions 44, 59, 62, 94, 105, 116, 124, 129,
135, 191; (b) one rare codon (CTA) for leucine at posi-
tions 18, 134, 173; (c) one rare codon (ATA) for isoleu-
cine at positions 66, 77, 96, 103, 115; and (d) one rare
codon (CCC) for proline at positions 122, 186
(Figure 4A). To find out whether CA expression couldFigure 3 Optimization of IPTG concentration and induction temperat
concentration: The pSA-Hp24-6His-transformed NiCo21 (DE3) E. coli cultures (0
and incubated at 30°C for 6 hours. Eight micro liter of cultures were mixed w
were transferred to NC membranes and immunoblot analysis was carried out
temperature: The pSA-Hp24-6His-transformed NiCo21(DE3) E.coli cultures (0.6O
C for 6, 12, and 18 hours respectively. Cultures were then processed to obtain
in Methods. Gels were stained with Coomassie Blue G250 and photographed
culture at 30°C (soluble); Lane 2, IPTG-induced culture at 30°C (insoluble); Lane
22°C (soluble); Lane 5, IPTG-induced culture at 22°C (insoluble); Lane 6, IPTG-in
(soluble); Lane 8, IPTG-induced culture at 18°C (insoluble); Lane 9, IPTG-inducebe improved by supplementing NiCo21(DE3) cells with
plasmids expressing rare tRNA, we transformed NiCo21
(DE3) with pACYC-RIL, pRARE2, and pLysSRARE2.
The pACYC-RIL plasmid supplies tRNA for four rare
codons (AUA, AGG, AGA, CUA), whereas pRARE2 for
seven rare codons (AUA, AGG, AGA, CUA, CCC, CGG,
and GGA). In addition to seven rare codons,ure for the expression of HIV-1 CA. Determination of optimal inducer
.6OD600) were added with varying concentrations (0–0.4 mM) of IPTG
ith 4X loading dye, boiled, and electrophoresed on 12% gels. Proteins
as described in Methods. (A). Determination of optimal induction
D600) were induced with 0.05 mM IPTG and incubated at 30, 22, and 18°
insoluble (IS) and soluble (S) fractions and electrophoresed as described
(B). Lane M1, BenchMark Pre-stained protein ladder; Lane 1: Un-induced
3, IPTG-induced culture at 30°C (soluble); Lane 4: Un-induced culture at
duced culture at 22°C (soluble); Lane 7: Un-induced culture at 18°C
d culture at 18°C (soluble).
Figure 4 Effect of rare tRNA supplementation on HIV-1 CA expression in NiCo21(DE3) E. coli. Rare codon analysis of open reading frame
(ORF) coding for HIV-1 p24 gene (A). NiCo21(DE3) E. coli were transformed with pACYC-RIL or pRARE2 or pRARE2-lysS and subsequently trans-
formed with pSA-Hp24-6His vectors and selected on LB + Cam + Amp plates. Cultures were grown in presence of Cam + Amp at 22°C for 12
hours, either induced with 0.05 mM IPTG, or un-induced. Cultures were processed to obtain whole cell lysate (WCL), insoluble (S), and soluble (S)
fractions. Samples were electrophoresed on 12% gel, stained with Coomassie Blue G250, and photographed (B). Lane M, BenchMark Pre-stained
protein ladder; Lanes WCL, whole cell lysate; Lanes IS, insoluble fraction; Lanes S, soluble fraction.
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background expression due to the presence of T7 lyso-
zyme. When expressed in the presence of rare tRNA
supplying plasmids, there was an improvement in CA
expression (Figure 4B). However, overexpressed protein
proportionally ended up in the insoluble fractions sug-
gesting that bacterial protein folding machinery was sat-
urated when CA was expressed in the presence of rare
tRNA. We did not see a significant change in CA ex-
pression between the NiCo21(DE3) containing pACYC-
RIL and pRARE2/pLysSRARE2. This suggests that
supplementation with 4 rare codons was sufficient to
improve CA expression. When compared side-by-side,
we found NiCo21(DE3)/pACYC-RIL produced highest
amount of CA (Figure 4B). Expression of CA in the
presence or absence of rare tRNA had minimal effect on
the growth of bacteria as determined by the total bio-
mass yield (9.1 g L-1 for NiCo21(DE3) and 8.96 g L-1 for
NiCo21(DE3) with pACYC-RIL). These experiments
were repeated at 18°C but distribution of recombinant
protein between soluble and insoluble fraction remained
the same, and incubation at lower temperature did not
result in more soluble CA (data not shown).
We also studied the effect of cultivation medium com-
position both on the growth of the NiCo21(DE3)-
pACYC-RIL and the production of the HIV-1 CA. Cellswere grown in M9, LB, Super, and Terrific broths at
22°C and in the presence of 1% glucose. Protein expression
was induced by adding 0.05 mM IPTG when the cells reach
to 0.5 OD600. Cells were harvested 12 hours post-induction
and analyzed by SDS-PAGE. The highest amount of
biomass (~27.7 g L-1 culture) was obtained in Super broth
followed by Terrific broth (~18.3 g L-1), and LB broth
(16.7 g L-1). Growth in M9 minimal broth resulted in the
lowest amount of biomass production (7.5 g L-1). Expres-
sion of CA was similar in LB, Super, and Terrific broth,
and lowest in M9 minimal broth when equal amount of
biomass subjected to SDS-PAGE analysis (Figure 5A).
However, since largest biomass was produced in Super
broth, it resulted into highest amount of HIV-1 CA
produced from 1L culture (Figure 5B).
Addition of 2-3% ethanol in culture medium [23,24]
and incubation at 42°C [25] leads to the overexpression
of chaperons, which in turn results in improved folding
and enhanced solubility of certain proteins. We tested
these conditions to improve the solubility of CA but did
not observe any effect (data not shown). When analyzed
using Wilkinson-Harrison statistical solubility model
[26], the HIV-1 CA-6His found to have a CV-CV’ value
of 0.57 and 63.8 percent chance of insolubility when
overexpressed in E. coli. In our case, percentage solubil-
ity based on the band density (density of soluble band
Figure 5 Effect of cultivation medium composition on production of HIV-1 CA. NiCo21(DE3)-pACYC-RIL expressing HIV-1 CA were grown in
various cultivation media supplemented with 1% glucose and 0.05 mM IPTG at 22°C for 12 hours. Cultures were adjusted to 1.5OD600 (to normalize
the biomass) and 8 uL of culture was analyzed using SDS-PAGE (A). M, Pre-stained protein ladder; Lanes UI, un-induced; Lanes I, IPTG-induced.
Comparison of HIV-1 CA production levels obtained using different growth media (B). Cells were harvested, lysed, and subjected to Chitin/IMAC
purification. Eluted protein was quantitated and HIV-1 CA produced from 1L of biomass was calculated.
Teow et al. BMC Biotechnology 2013, 13:107 Page 8 of 14
http://www.biomedcentral.com/1472-6750/13/107divided by the density of the soluble plus insoluble
bands) was 60.65% and 65.35% for NiCo21(DE3) and
NiCo21(DE3)-pACYC-RIL respectively. Based on our re-
sults and Wilkinson-Harrison statistical solubility model,
we anticipate that CA may not be expressed 100% in sol-
uble state, unless it is expressed as fusion protein with
solubility enhancing partner such as maltose binding
protein (MBP), NusA etc.
Purification of HIV-1 CA from pSA-Hp24-6His-transfected
NiCo21(DE3) E. coli
BL21(DE3) is a widely used E. coli strain for recombin-
ant protein overexpression. Like other E. coli strains,
BL21(DE3) contains a number of host proteins that are
rich in nonconsecutive histidine residues. These
histidine-rich proteins co-purify during IMAC proce-
dures rendering recombinant protein preparations im-
pure. The NiCo21(DE3) is a derivative of BL21(DE3) in
which three histidine-rich proteins (slyD, can, arnA) are
tagged with chitin binding domain and in one (glmS),
the histidine-rich motifs are replaced with alanine [27].
Pre-adsorption of bacterial cell lysates on chitin beads
results in the removal of major host histidine-rich pro-
teins. Depleted fractions are then subjected to IMAC,
which yields highly pure 6His-tagged recombinantprotein preparations. We lysed the pSA-Hp24-6His-
transformed NiCo21(DE3) and subjected the lysates to
IMAC (Co2+ beads) alone, chitin beads alone, and chitin
beads + IMAC purification. A considerable amount of
contaminating proteins (shown by the arrowheads) co-
purified with HIV- CA when purified using IMAC alone
(Figure 6A, lane 1) or chitin beads alone (Figure 6A,
lane 2). On the other hand, the HIV-1 CA was purified
with un-noticeable (on Coomassie-stained gels) host
protein contamination (Figure 6A, lane 3) when subjected
to chitin beads + IMAC purification strategy. In some
experiments, we first performed IMAC, and imidazole
eluate was then treated with chitin beads to remove the
host histidine-rich proteins. However, results were not as
good, perhaps due to the presence of 150 mM imidazole
in the eluate (results not shown).
To further demonstrate the purification efficiency, we
treated the HIV-1 CA overexpressing NiCo21(DE3) ly-
sates with chitin beads and subjected the chitin bead-
treated lysates to TALON® Superflow™ cobalt-based
IMAC column on FPLC system. The recombinant CA
was eluted with a linear (5-150 mM) imidazole gradient.
Elution of CA was monitored by absorbance at 280 nm.
A representative FPLC chromatogram shows a single
peak eluting at 150 mM imidazole, spanning A6-A11
Figure 6 Purification of HIV-1 CA expressed in NiCo21(DE3) E. coli. NiCo21(DE3)-pACYC-RIL expressing HIV-1 CA were grown in presence of
0.05 mM IPTG at 22°C for 12 hours and processed to purify recombinant protein using Co2+ resin, chitin resin, and Chitin + Co2+ resins. Sample
collected during the procedure were analyzed by SDS-PAGE (A) and western blot (B). Lane M, BenchMark Pre-stained protein ladder; Lane M1,
MagicMark XP Western Protein Standard; Lane 1, CA purified on Co2+ resin; Lane 2, CA purified on chitin resin; Lane 3, CA sequentially purified on
chitin and Co2+ resins. Red arrowheads show contaminating proteins when CA was purified using Co2+ resin alone (Lane 1).
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analysis, which shows a single 24 kDa band in all six frac-
tions. The eluted protein in these fractions did not appear
to be contaminated with other proteins (Figure 7).
Using the purification scheme described above, we
yielded >6 mg of purified HIV-1 CA from 1g biomass of
pSA-Hp24-6His-transformed NiCo21(DE3)/pACYC-RIL
when propagated in super broth and induced with
0.05 mM IPTG for 12h at 21°C. The average yield andFigure 7 FPLC and electrophoretic analysis of HIV-1 CA. HIV-1 CA was
FPLC system. SDS/PAGE (12%) analysis results (inset) of the eluted fractions
pooled as the high purity product. Lane M, BenchMark Pre-stained protein
A6-A11, CA eluted in imidazole gradient.percentage recovery of recombinant HIV-1 CA from
three independent 100 mL expression cultures is given in
the Table 1.
Antigenicity of recombinant HIV-1 CA
This work is part of a project in which we are generating
anti-CA antibody phage display library (manuscript in
preparation). The ELISA plates coated with recombinant
CA were used to determine the serum titer ofpurified using TALON® Superflow™ cobalt-based IMAC column on an
as shown in the FPLC chromatogram. Fractions A6 to A11 were
ladder; Lanes W1/W2, unbound protein in wash fractions; Lanes
Table 1 Yield and percentage recovery of recombinant
HIV-1 CA
Sample Total protein (mg) HIV CA (mg) Purity (%)
Soluble lysate 288 39 13.5
Chitin beads 166 25 15.06
IMAC 17.5 17 97.1
NiCo21(DE3)-pACYC-RIL expressing HIV-1 CA were grown in super broth the
presence of 0.05 mM IPTG at 22°C for 12 hours and processed to purify recom-
binant protein as described in Methods. Quantities of recombinant HIV-1 CA
are based on average values from three independent 100 mL expression cul-
tures. HIV-1 CA was quantified by densitometry of bands on a western blots
and the Qubit fluorometric total protein assay.
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mRNA from the spleens. Serum was diluted 1:10, 1:100,
1:1000, 1:10,000, and 1:100,000 respectively and assayed
using indirect ELISA. Pre-immune serum was used as
negative control. As shown in Figure 8A, the titer was
higher than 1:100,000.
The antiserum was also used for immunoblot analysis
of the cell lysates of pNL4.3-transfected/HIV-1 (NL4.3)-
producing 293T cells and mock-transfected 293T cells
(as negative control). Recombinant HIV-1 CA was used
as the positive control. The antiserum specifically
reacted with pNL4.3-transfected 293T cells and recom-
binant CA but not with the un-transfected 293T cells
(Figure 8B). These results show that the recombinant
CA had correct immunogenicity profile.
Polymerization competency of HIV-1 CA
To show that purified CA was biologically active (cap-
able of polymerizing), we subjected the recombinant
protein to an in vitro polymerization assay. The recom-
binant CA was allowed to polymerize under high salt
conditions and the change in turbidity (measured at
350 nm) over time (up to 60 min) was recorded. Kinetic
traces of CA exhibited a typical sigmoidal time-
dependent protein aggregation/polymerization curve forFigure 8 Antigenicity of HIV-1 CA. We immunized mice with purified CA
diluted and subjected to indirect ELISA. The pre-immune serum served as t
plasmid and cell lysates were analyzed by SDS-PAGE and Western blotting
Western Protein Standard; Lane 1, mock-transfected 293T cell lysate; Lane 2
4, purified CA (100 ng).80, 60 and 50 μM CA (Figure 9A). Curves obtained for
40 μM CA showed a lag phase (Figure 9A) that was due
to the low concentration of CA and characteristic of a
nucleation step. These results showed that purified
CA was biologically active and suitable to study
polymerization/inhibition of polymerization of the intact
capsid protein (CA) of HIV-1 into mature capsid-like
particles.
To further demonstrate that the purified HIV-CA
could be used for the identification of CA assembly in-
hibitors, we incubated 50 μM HIV-1 CA with varying
concentrations (1,5,10 μM) of CA-specific anti-p24 anti-
body. Incubation of HIV-CA with anti-p24 anti-
body resulted in a dose-dependent inhibition of CA
polymerization. Incubation with 10 μM anti-p24 resulted
in a complete inhibition of CA assembly, whereas
5 μM antibody delayed the rate of CA polymerization
(Figure 9B). To rule out the possibility of non-specific
inhibition of CA assembly due to the presence of large
antibody molecules in the reaction mix, we incubated
the HIV-1 CA with anti-AChE antibody. Presence of
20 μM (twice as much as anti-p24) anti-AChE had no
effect on CA polymerization (Figure 9B). This suggests
that CA polymerization inhibition in the presence of
anti-p24 was due to the specific binding to the CA
molecules.
Discussion
Emergence of anti-retroviral (ARV) drug-resistant qua-
sispecies of HIV is a major obstacle in the effective treat-
ment of AIDS. To cope with the drug resistant mutants,
there is a constant need of developing newer and better
therapeutic regimens against novel targets. Due to its
important role in both late and early stages of the HIV
replication cycle, CA has attracted considerable atten-
tion as a potential target in recent years. Chemical com-
pounds and peptides interfering with the capsidas described in Methods. The sera from immunized mice were serially
he negative control (A). 293T cells were transfected with the pNL4-3
using serum from CA-immunized mice (B). Lane M1, MagicMark XP
, pNL4.3-transfected 293T cell lysate; Lane 3, purified CA (10 ng); Lane
Figure 9 Polymerization competency of HIV-1 CA. Purified CA (40-80 μM) was mixed with 50 mM sodium phosphate buffer (pH 8.0) and the
polymerization was induced by the addition of 2.0 M NaCl solution. Polymerization was monitored by measuring absorbance at 350 nm every 10 s
for up to 60 min (A). To further confirm that purified HIV-1 CA could be used for the identification of CA assembly inhibitors, we incubated 50 μM
HIV-1 CA with varying concentrations (1,5,10 μM) of CA-specific anti-p24 MAb. Anti-Acetylcholinesterase antibody was used as a negative
control (B).
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rions and prevented their release from the cells [2-6].
These studies typically need milligram quantities of
highly pure and polymerization-competent CA. Due to
the high cost of commercially available CA, it would by
highly desirable to produce it in-house.
Bacterium Escherichia coli is by far the most robust
and economical in vivo system for the production of
heterologous recombinant proteins in scalable quan-
tities. Unfortunately, HIV-1 CA expresses poorly in E.
coli due to its use of rare codons. Codon optimization is
one possibility but it can prove tedious and costly. Fur-
thermore, codon optimization does not guarantee high
yields of soluble protein since bacterial folding machin-
ery can get saturated due to the high turnover rate of
protein synthesis, and produced protein can end up in
the inclusion bodies [22]. An alternative of codonoptimization is to transform the expression host with
plasmids expressing rare tRNA. We anticipated that the
use of a host strain supplemented with rare tRNA
should result in higher yields of recombinant CA. In-
deed, when expressed in NiCo21(DE3) containing rare
tRNA-expressing plasmids pACYC-RIL and/or pRARE2,
there was a significant improvement in the yield of re-
combinant HIV-1 CA. Plasmid pACYC-RIL supplies
tRNA for arginine (AGA, AGG), isoleucine (AUA), and
leucine (CUA) whereas pRARE2 supplies tRNA for ar-
ginine (AGA, AGG, CGG), isoleucine (AUA), leucine
(CUA), proline (CCC), and glycine (GGA). However,
protein expression was indifferent between the bacteria
carrying pACYC-RIL or pRARE2. The highest number
of rare codons in p24 gene are for arginine (10 rare co-
dons) followed by isoleucine (4 rare codons), leucine
(3 rare codons), and proline (2 rare codons). It appears that
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(arginine, isoleucine, and leucine) was sufficient to improve
the protein yield.
Lab-scale purification of HIV-1 CA has also been
hampered due to its poor solubility when overexpressed
in E. coli. While it is possible to purify functional pro-
teins from the inclusion bodies, it is a time consuming
process and increases the cost of production. Attempts
have been made to improve the solubility of HIV-1 CA
by gene modification. For instance, it has been reported
that solubility can be improved by introducing a Cyst-
eine at 230 position, which makes a disulfide bond with
Cys210 and promotes proper folding of recombinant CA
[10]. It was also shown that the substitutions of certain
amino acids had no effect on the immunogenicity of the
recombinant protein [10]. However, whether these
changes would have altered the polymerization compe-
tence of CA was not discussed. Since the recombinant
CA produced in present study was intended to be used
for generating/screening anti-CA phage display library
and screening polymerization inhibiting single chain Fv
antibodies, we used wild-type sequence. By systematic-
ally optimizing the culture conditions (IPTG concentra-
tion, temperature, culture medium composition), we
managed to produce milligram quantities of recombin-
ant protein in soluble state. It would be interesting to
note that as little as 0.05 mM IPTG was sufficient to in-
duce the recombinant protein expression. Use of less
IPTG in the culture medium would also result in the
economical production of recombinant protein. Even
though the ratio of soluble vs insoluble protein was
highest for cultures incubated at 18°C, the final yield
was greatest when the cultures were incubated at room
temperature (22 ±2°C). Room temperature incubation is
also convenient and economical compared to 18°C,
which needs refrigerated incubators.
IMAC is one of the most popular methods for the
purification of poly-histidine-tagged recombinant pro-
teins. Unfortunately, poly-histidine-tagged recombinant
proteins that are isolated by IMAC are frequently con-
taminated with endogenous E. coli metal binding pro-
teins. Some 17 E. coli IMAC contaminating proteins
have been described, 15 of which elute from Ni-NTA at
>55 mM imidazole. These contaminating proteins in-
clude CRP, Fur, ArgE, DnaK, SlyD, GlmS, GlgA, ODO1,
ODO2, Can (YadF), ArnA (YfbG), AceE, GroES, and
GroEL. Since His-tagged proteins are typically eluted be-
tween 60-150 mM imidazole, the IMAC contaminants
co-elute rendering target protein preparations impure.
Secondary chromatographic steps, e.g., size exclusion,
protein specific (Heparin affinity), immunoaffinity, and
dual affinity tag chromatography have been suggested.
However, these additional procedures result in more op-
erative time, additional cost, and lower overall yields.To address this problem, Robichon et al. has described
NiCo21(DE3) strain specifically engineered to minimize
major E. coli protein contaminants (SlyD, GlmS, Can,
ArnA) of IMAC fractions [27]. This strain expresses the
endogenous proteins SlyD, Can, and ArnA fused at their
C terminus to a chitin binding domain (CBD) and the
protein GlmS, with six surface histidines replaced by ala-
nines [27]. Desired recombinant protein(s) produced in
NiCo21(DE3) are separated from CBD-tagged IMAC
contaminating proteins by adsorbing them on chitin
beads.
As shown in the results, purification of HIV-1 CA
using IMAC alone resulted in CA contaminated with
several host proteins. When the soluble lysate was pre-
treated with chitin beads and then subjected to IMAC,
highly pure CA was obtained. The only downside of this
purification scheme is the employment of two successive
purification steps, one using chitin beads, and second
using IMAC. However, this scheme of purification is still
better than those where additional chromatographic
steps are employed. Chitin beads are cheap, can be re-
generated multiple times, and above all, compatible with
commonly used IMAC buffers. The loss of desired pro-
tein in chitin bead pre-treatment was minimal in our
case. While in process of preparing this manuscript, An-
dersen et al. reported the use of LOBSTR, a derivative of
E. coli BL21(DE3) that carries gnomically modified cop-
ies of arnA and slyD [28]. Proteins translated from these
modified genes exhibited reduced affinities to IMAC,
resulting in higher purity of overexpressed heterologous
proteins. While only two of the four major metal binding
proteins are modified for reduced affinity to IMAC, use
of LOBSTR has shown to result in significantly im-
proved purification and without the additional chitin
resin adsorption step. This will both reduce the cost and
time.
We showed that the recombinant HIV-1 CA produced
in this work was biologically active in the polymerization
assay. We also showed that the polymerization of HIV-1
CA could be inhibited following its incubation with CA-
specific anti-p24 antibody. We incubated the CA with an
unrelated anti-AChE antibody and demonstrated that CA
polymerization was specifically inhibited by the anti-p24
antibody. These data indicate that CA polymerization
assay could be used to screen CA polymerization-
inhibiting antibodies. CA is an intracellular target and
therefore off-limit to antibodies that normally do not
penetrate into the cytoplasm. However, strategies are be-
ing devised to develop antibodies capable of crossing the
plasma membrane and interacting with intracellular
targets [29-31].
A recent report has described the purification of HIV-1
CA using its intrinsic tendency to polymerize and
depolymerize. Isolation of protein using this technique
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polymerization competent CA [11]. While the technique
is novel, it still involves several steps, from ammonium
sulfate precipitation to polymerization/de-polymerization,
multiple dialyses, and anion exchange chromatography.
The route we took to purify CA is conventional but it in-
volves fewer steps and is highly reproducible. Use of ap-
proach described here has resulted in as much protein
yield as compared to the method reported by Hung et al.
(>6 mg versus 5-7 mg from each one gram of bacterial
biomass). By cultivating the bacteria in Super broth, twice
as much capsid protein can be produced from 1 L of the
culture.
Conclusion
In the current paper, we report on a methodical analysis
of HIV-1 CA expression in E. coli based on the combin-
ation of expression vector, E. coli strain selection, and
analysis of cultivation conditions and fermentation
broth. The simple expression and purification procedure
described in this work resulted in the production of
highly pure and biologically active HIV-1 CA in good
yields for potential use in drug discovery, diagnostics,
and in vaccine production.
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